Udvalget besluttede, at fordelene ved Aldurazyme var større end risiciene for en langsigtet enzymsubstitutionsbehandling af patienter med den bekræftede diagnose mucopolysaccharidosis I.
The Committee decided that Aldurazyme’ s benefits are greater than its risks for long-term enzyme replacement therapy in patients with a confirmed diagnosis of MPS I.